Skip Navigation

European Heart Journal 1993 14(Supplement H):93-99; doi:10.1093/eurheartj/14.suppl_H.93
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Katritsis, D.
Right arrow Articles by Camm, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katritsis, D.
Right arrow Articles by Camm, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

New class III antiarrhythmic drugs

D. Katritsis and A. J. Camm

Department of Cardiological Sciences, St George's Hospital Medical School London, U.K.

Correspondence: Dr D. Katritsis, Department of Cardiological Sciences, St George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, U.K.

Several new antiarrhythmic compounds with pure class III activity are currently under development and seem to possess considerable antiarrhythmic potential. The primary electrophysiological action of class III agents is selective prolongation of repolarization without conduction slowing. This effect is usually mediated by block of one or more potassium currents which results in prolongation of the action-potential duration and refractoriness in both atrial and ventricular myocardium. The magnitude of increases in effective refractory period decreases as the heart rate is increased, i.e. these drugs display ‘reverse use-dependence’.

Initial animal and clinical studies have shown that class III agents are effective against re-entrant supraventricular and ventricular arrhythmias without having any important negative inotropic effect in the compromized ventricle. Animal studies have also suggested thai these drugs may be useful in suppressing postinfarction arrhythmias and preventing arrhythmic sudden death. However, concerns have been raised by reports of substantial proarrhythmic tendency associated with these drugs, mainly in the form oftorsade depointes. Careful clinical evaluation is required to establish the clinical benefits of these potentially promising new compounds.

Key Words: Class III antiarrhythmics • sotalol • d-sotalol • dofetilide • E-4031 • sematilide • proarrhythmia • potassium channels


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
C. de Wit
Different pathways with distinct properties conduct dilations in the microcirculation in vivo
Cardiovasc Res, October 31, 2009; (2009) cvp340v2.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G.-J. Chang, M.-J. Su, S.-C. Kuo, T.-P. Lin, and Y.-S. Lee
Multiple Cellular Electrophysiological Effects of a Novel Antiarrhythmic Furoquinoline Derivative HA-7 [N-Benzyl-7-methoxy-2,3,4,9-tetrahydrofuro[2,3-b]quinoline-3,4-dione] in Guinea Pig Cardiac Preparations
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 380 - 391.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. P. Nase, J. Tuttle, and H. G. Bohlen
Reduced perivascular PO2 increases nitric oxide release from endothelial cells
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H507 - H515.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L Bianconi, A Castro, M Dinelli, P Alboni, A Pappalardo, E Richiardi, and M Santini
Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study
Eur. Heart J., August 1, 2000; 21(15): 1265 - 1273.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.